FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Authors:
- Vanja VaccaroVVVanja Vaccaro
- Isabella SperdutiISIsabella Sperduti
- Michele MilellaMMMichele Milella
- 25 August 2011
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 365 (8) , 768-769
Abstract
Conroy et al. (May 12 issue)1 report that FOLFIRINOX (a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin) provided a statistically and clinically significant benefit over single-agent gemcitabine in patients with advanced pancreatic cancer. Although the increased toxicity associated with this combination therapy may temper enthusiasm, this is the first real advance in such therapy since the introduction of gemcitabine. It has been debated whether gemcitabine-based combination therapies provide any additional benefit, and meta-analyses have reached conflicting conclusions.2-4 A sensitivity analysis of data pooled from seven randomized trials involving 2422 patients in which single-agent gemcitabine was compared with gemcitabine in combination with cisplatin, oxaliplatin, or capecitabine indicates that the use of gemcitabine-based doublets had a clinically negligible, although statistically significant, absolute survival benefit ( Table 1 ). However, power calculations reliably (80% power, two-tailed alpha of 0.05) rule out the possibility that gemcitabine-based doublets could improve 1-year survival by more than 5%. In that respect, the results of the FOLFIRINOX study strongly suggest that moving away from using gemcitabine alone versus using gemcitabine-based combinations is actually a wiser, more creative, and more effective strategy to improve outcomes in patients with advanced pancreatic cancer. In addition, trials of such combination chemotherapy regimens could foster the development of molecularly targeted agents in this disease.5Keywords
This publication has 7 references indexed in Scilit:
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?The Lancet Oncology, 2011
- Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancerBMC Cancer, 2008
- Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter studyAnnals of Oncology, 2007
- Gemcitabine‐based combinations for inoperable pancreatic cancer: Have we made real progress?Cancer, 2007
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2007
- Meta-analyses of randomised clinical trials in oncologyThe Lancet Oncology, 2001